Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
MNTA's Cash-to-Debt is ranked higher than
100% of the 815 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.12 vs. MNTA: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
MNTA' s Cash-to-Debt Range Over the Past 10 Years
Min: 10.74  Med: 119.91 Max: No Debt
Current: No Debt
Equity-to-Asset 0.71
MNTA's Equity-to-Asset is ranked higher than
61% of the 739 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. MNTA: 0.71 )
Ranked among companies with meaningful Equity-to-Asset only.
MNTA' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.49  Med: 0.85 Max: 0.96
Current: 0.71
-0.49
0.96
Interest Coverage No Debt
MNTA's Interest Coverage is ranked higher than
99% of the 638 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 118.48 vs. MNTA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
MNTA' s Interest Coverage Range Over the Past 10 Years
Min: 110.84  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 4.92
Beneish M-Score: -4.26
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -71.11
MNTA's Operating Margin % is ranked lower than
84% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. MNTA: -71.11 )
Ranked among companies with meaningful Operating Margin % only.
MNTA' s Operating Margin % Range Over the Past 10 Years
Min: -448.33  Med: -142.21 Max: 63.48
Current: -71.11
-448.33
63.48
Net Margin % -24.70
MNTA's Net Margin % is ranked lower than
81% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.26 vs. MNTA: -24.70 )
Ranked among companies with meaningful Net Margin % only.
MNTA' s Net Margin % Range Over the Past 10 Years
Min: -429.9  Med: -140.82 Max: 63.71
Current: -24.7
-429.9
63.71
ROE % -8.19
MNTA's ROE % is ranked lower than
76% of the 792 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. MNTA: -8.19 )
Ranked among companies with meaningful ROE % only.
MNTA' s ROE % Range Over the Past 10 Years
Min: -66.11  Med: -31.66 Max: 59.21
Current: -8.19
-66.11
59.21
ROA % -6.34
MNTA's ROA % is ranked lower than
75% of the 821 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. MNTA: -6.34 )
Ranked among companies with meaningful ROA % only.
MNTA' s ROA % Range Over the Past 10 Years
Min: -51.08  Med: -27.29 Max: 55.62
Current: -6.34
-51.08
55.62
ROC (Joel Greenblatt) % -365.76
MNTA's ROC (Joel Greenblatt) % is ranked lower than
87% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.07 vs. MNTA: -365.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MNTA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -529.82  Med: -376.75 Max: 349.83
Current: -365.76
-529.82
349.83
3-Year Revenue Growth Rate 31.80
MNTA's 3-Year Revenue Growth Rate is ranked higher than
92% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. MNTA: 31.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MNTA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 1.8 Max: 139.6
Current: 31.8
0
139.6
3-Year EBITDA Growth Rate -21.70
MNTA's 3-Year EBITDA Growth Rate is ranked lower than
89% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. MNTA: -21.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MNTA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -45.2  Med: -9 Max: 30.4
Current: -21.7
-45.2
30.4
3-Year EPS without NRI Growth Rate -47.40
MNTA's 3-Year EPS without NRI Growth Rate is ranked lower than
95% of the 580 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.90 vs. MNTA: -47.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MNTA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.2  Med: -9.6 Max: 30.1
Current: -47.4
-48.2
30.1
GuruFocus has detected 3 Warning Signs with Momenta Pharmaceuticals Inc $MNTA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MNTA's 30-Y Financials

Financials (Next Earnings Date: 2017-08-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325414    SIC: 2836
Compare:NAS:EGRX, NYSE:DPLO, NAS:IPXL, OTCPK:GNMLF, NAS:PAHC, OTCPK:KHTRF, OTCPK:NPPNY, NAS:SGYP, OTCPK:TWMJF, OTCPK:CSWYF, NAS:INNL, OTCPK:TZHGF, NAS:AMPH, NAS:HRTX, NAS:PCRX, NAS:HZNP, NYSE:LCI, NAS:DEPO, OTCPK:LPCUF, NAS:FLXN » details
Traded in other countries:LZ1.Germany,
Headquarter Location:USA
Momenta Pharmaceuticals Inc is a biotechnology company. It is engaged in developing generic versions of complex drugs, biosimilars and novel therapeutics for oncology and autoimmune disease.

Momenta is a biotechnology company based in Cambridge, Mass. Using technology developed at the Massachusetts Institute of Technology, it focuses on the characterization and development of innovative and complex generic drug molecules. Its first and only product is a bioequivalent generic version of Lovenox, sold through a partnership with Novartis. The company received an approval for a generic version of Copaxone in early 2015 and has other innovative biologic drugs and biosimilars under development.

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 41.24
MNTA's Price-to-Owner-Earnings is ranked lower than
63% of the 304 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.00 vs. MNTA: 41.24 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MNTA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.23  Med: 7.83 Max: 43.46
Current: 41.24
3.23
43.46
PB Ratio 3.47
MNTA's PB Ratio is ranked lower than
61% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. MNTA: 3.47 )
Ranked among companies with meaningful PB Ratio only.
MNTA' s PB Ratio Range Over the Past 10 Years
Min: 1.34  Med: 2.95 Max: 13.69
Current: 3.47
1.34
13.69
PS Ratio 10.45
MNTA's PS Ratio is ranked lower than
81% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. MNTA: 10.45 )
Ranked among companies with meaningful PS Ratio only.
MNTA' s PS Ratio Range Over the Past 10 Years
Min: 1.84  Med: 13.86 Max: 57.26
Current: 10.45
1.84
57.26
Price-to-Free-Cash-Flow 24.17
MNTA's Price-to-Free-Cash-Flow is ranked higher than
52% of the 209 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.35 vs. MNTA: 24.17 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MNTA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.02  Med: 8.29 Max: 622.58
Current: 24.17
3.02
622.58
Price-to-Operating-Cash-Flow 21.71
MNTA's Price-to-Operating-Cash-Flow is ranked lower than
57% of the 281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.13 vs. MNTA: 21.71 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MNTA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.92  Med: 8.03 Max: 170.8
Current: 21.71
2.92
170.8
Current Ratio 4.10
MNTA's Current Ratio is ranked higher than
70% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. MNTA: 4.10 )
Ranked among companies with meaningful Current Ratio only.
MNTA' s Current Ratio Range Over the Past 10 Years
Min: 4.1  Med: 10.69 Max: 28.87
Current: 4.1
4.1
28.87
Quick Ratio 4.10
MNTA's Quick Ratio is ranked higher than
76% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. MNTA: 4.10 )
Ranked among companies with meaningful Quick Ratio only.
MNTA' s Quick Ratio Range Over the Past 10 Years
Min: 4.1  Med: 10.69 Max: 28.87
Current: 4.1
4.1
28.87
Days Sales Outstanding 83.25
MNTA's Days Sales Outstanding is ranked lower than
57% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. MNTA: 83.25 )
Ranked among companies with meaningful Days Sales Outstanding only.
MNTA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.32  Med: 86.25 Max: 233.89
Current: 83.25
36.32
233.89

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.80
MNTA's 3-Year Average Share Buyback Ratio is ranked lower than
72% of the 477 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. MNTA: -10.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MNTA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -218.2  Med: -10.45 Max: -1.7
Current: -10.8
-218.2
-1.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 4.51
MNTA's Price-to-Net-Cash is ranked higher than
77% of the 243 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.42 vs. MNTA: 4.51 )
Ranked among companies with meaningful Price-to-Net-Cash only.
MNTA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.03  Med: 4.02 Max: 14.33
Current: 4.51
2.03
14.33
Price-to-Net-Current-Asset-Value 4.01
MNTA's Price-to-Net-Current-Asset-Value is ranked higher than
73% of the 521 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.35 vs. MNTA: 4.01 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
MNTA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.55  Med: 3.51 Max: 11.36
Current: 4.01
1.55
11.36
Price-to-Tangible-Book 3.52
MNTA's Price-to-Tangible-Book is ranked lower than
51% of the 701 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. MNTA: 3.52 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MNTA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.5  Med: 3.07 Max: 10.13
Current: 3.52
1.5
10.13
Price-to-Intrinsic-Value-Projected-FCF 4.62
MNTA's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
70% of the 329 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. MNTA: 4.62 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MNTA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.77  Med: 3.69 Max: 8.31
Current: 4.62
1.77
8.31
Price-to-Median-PS-Value 0.75
MNTA's Price-to-Median-PS-Value is ranked higher than
79% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. MNTA: 0.75 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MNTA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13  Med: 1.07 Max: 3.93
Current: 0.75
0.13
3.93
Earnings Yield (Greenblatt) % -9.49
MNTA's Earnings Yield (Greenblatt) % is ranked lower than
84% of the 820 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. MNTA: -9.49 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MNTA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -158.2  Med: -17.3 Max: 78.3
Current: -9.49
-158.2
78.3

More Statistics

Revenue (TTM) (Mil) $116.38
EPS (TTM) $ -0.43
Beta2.02
Short Percentage of Float9.38%
52-Week Range $9.66 - 19.90
Shares Outstanding (Mil)74.20

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 123 178 168
EPS ($) -1.47 -0.93 -1.31
EPS without NRI ($) -1.47 -0.93 -1.31
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for MNTA

Headlines

Articles On GuruFocus.com
Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 38th Annual Global Healthcare C Jun 07 2017 
Momenta Pharmaceuticals Appoints Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer Jun 01 2017 
UPDATE -- Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences May 10 2017 
Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences May 10 2017 
Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results May 02 2017 
Momenta Pharmaceuticals to Webcast Presentation at the Deutsche Bank 42nd Annual Health Care Confere Apr 26 2017 
Momenta Pharmaceuticals Announces Date of First Quarter 2017 Financial Results Conference Call and W Apr 18 2017 
Momenta Pharmaceuticals Announces Positive Results for Humira Biosimilar Nov 30 2016 
Very Low P/E Stocks Joel Greenblatt selected Dec 22 2011 
Momenta Pharmaceuticals Inc. (MNTA) SVP, CFO Richard P Shea sells 979 Shares Feb 24 2011 

More From Other Websites
ETFs with exposure to Momenta Pharmaceuticals, Inc. : June 27, 2017 Jun 27 2017
Mylan In FDA Limbo On Generic Multiple Sclerosis Drug Jun 15 2017
Implied Volatility Surging for Momenta Pharmaceuticals (MNTA) Stock Options Jun 13 2017
Momenta Pharmaceuticals, Inc. :MNTA-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017 Jun 09 2017
Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 38th Annual Global Healthcare... Jun 07 2017
Why Is Momenta Pharmaceuticals (MNTA) Down 9.7% Since the Last Earnings Report? Jun 05 2017
Momenta Pharmaceuticals Appoints Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer Jun 01 2017
Novartis CEO sees no need for big takeover May 31 2017
UPDATE -- Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences May 10 2017
Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences May 10 2017
Edited Transcript of MNTA earnings conference call or presentation 2-May-17 2:00pm GMT May 04 2017
Momenta Pharmaceuticals, Inc. Looks for Some Momentum May 03 2017
Momenta (MNTA) Q1 Loss Narrower than Expected, Sales Beat May 03 2017
Momenta Pharmaceuticals, Inc. – Value Analysis (NASDAQ:MNTA) : May 2, 2017 May 02 2017
Momenta reports 1Q loss May 02 2017
Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results May 02 2017
Investor Network: Momenta Pharmaceuticals, Inc. to Host Earnings Call May 02 2017
Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MNTA-US : May... May 01 2017
Momenta Pharmaceuticals to Webcast Presentation at the Deutsche Bank 42nd Annual Health Care... Apr 26 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}